Adicet Bio, Inc. (ACET) — Current Report

AI-Powered SEC Filing Analysis

← All ACET filings

Want the newest filings?

This analysis covers the filing from 2026-04-28. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Earlier Current Report filings

Filed: 2026-01-07
  • Adicet Bio has doubled enrollment in its prulacabtagene leucel (prula-cel) Phase 1 program for autoimmune diseases, indicating progress in its clinical development.
  • The company has reached alignment with the FDA to allow patients with lupus nephritis and systemic lupus erythematosus to be dosed with prula-cel in the outpatient setting, potentially improving access and convenience for patients.
  • Adicet plans to submit a regulatory filing for ADI-212 in metastatic castration-resistant prostate cancer in the first half of 2026, potentially expanding its pipeline and addressing an unmet medical need.

Other reports for Adicet Bio, Inc.

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.